移植物抗淋巴瘤效应对接受减低强度预处理-阿仑单抗异基因造血干细胞移植的成熟淋巴系统恶性肿瘤患者结局的影响
该回顾性研究纳入2000至2012年间接受减低强度预处理-阿仑单抗异基因造血干细胞移植的288例成熟淋巴系统恶性肿瘤患者,中位随访64个月,5年总生存率47%、复发率33%。多因素分析显示发生移植物抗宿主病(P=0.03)及无关供者类型(P=0.03)为复发的保护因素,支持移植物抗淋巴瘤效应是移植后防止复发的关键保护因素。
要点
- 5年总生存率47%、复发率33%、无移植物抗宿主病/复发生存率37%、非复发死亡率28%。
- 多因素分析显示发生移植物抗宿主病(P=0.03)和无关供者类型(P=0.03)为复发的保护因素。
- 预防性供者淋巴细胞输注使78%患者转为完全或稳定混合供者嵌合,治疗性输注使56%患者达到同样效果。
核心结论
- 这些数据表明接受减低强度预处理-阿仑单抗异基因造血干细胞移植的成熟淋巴系统恶性肿瘤患者具有较好的长期结局,并支持移植物抗淋巴瘤效应是移植后防止复发的关键保护因素这一概念。
研究设计与样本
- 回顾性研究纳入288例于2000年至2012年间接受减低强度预处理-阿仑单抗异基因造血干细胞移植的成熟淋巴系统恶性肿瘤患者,其中非霍奇金淋巴瘤57%、霍奇金淋巴瘤24%、慢性淋巴细胞白血病19%,58%为复发/难治状态;存活者中位随访64个月。
主要发现
- 5年总生存率、复发率、无移植物抗宿主病/复发生存率和非复发死亡率分别为47%、33%、37%和28%。
- II-IV级急性移植物抗宿主病和广泛型慢性移植物抗宿主病的累积发生率在100天和5年时分别为22%和21%。
- 多因素分析显示发生移植物抗宿主病(P=0.03)和无关供者类型(P=0.03)为复发的保护因素。
- 288例中62例接受了供者淋巴细胞输注,其中因混合供者嵌合行预防性输注37例,因临床复发行治疗性输注25例。
- 预防性供者淋巴细胞输注使78%患者转为完全或稳定混合供者嵌合,治疗性输注使56%患者达到同样效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic haematopoietic stem cell transplant (allo-HSCT) offers potentially curative therapy for patients with relapsed/refractory lymphoid malignancies. Reduced-intensity conditioning (RIC) with Alemtuzumab reduces transplant-related mortality and graft-versus-host disease (GvHD), but may be associated with increased risk of relapse. With the aim of studying the effect of GVHD and donor lymphocyte infusions (DLI) on relapse, we performed a retrospective study of 288 patients (57% non-Hodgkin lymphoma, 24% Hodgkin lymphoma and 19% chronic lymphocytic leukaemia; 58% were relapsed/refractory) who underwent RIC-Alemtuzumab-HSCT between 2000 and 2012. Median follow-up time for survivors was 64 months. Five-year overall survival, relapse incidence, GvHD/relapse-free survival and non-relapse mortality were 47%, 33%, 37% and 28% respectively. Cumulative incidence of grade II-IV acute and extensive chronic GvHD was 22% and 21% at 100 days and 5 years respectively. On multivariate analysis, presence of GvHD (P = 0·03) and unrelated donor type (P = 0·03) were protective of relapse. 62/288 patients received DLI for either mixed donor chimerism (prophylactic DLI, n = 37) or clinical relapse (therapeutic DLI, n = 25). Prophylactic and therapeutic DLI successfully converted the patient to full or stable mixed donor chimerism in 78% and 56% of patients respectively. These data demonstrate good long-term outcomes and support the concept of the graft-vs-lymphoma effect as a key protective factor against relapse following RIC-Alemtuzumab allo-HSCT for patients with mature lymphoid malignancies.
引用
- Brierley CK, Jones FM, Hanlon K, et al. Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies. Br J Haematol. 2018. PMID: 30467838. doi:10.1111/bjh.15685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。